Literature DB >> 11535143

Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required.

R S Patel1, G W McGarry.   

Abstract

Otolaryngologists and general practitioners commonly prescribed intranasal corticosteroid drops for rhinitis. Compliance in real patients has not previously been studied, but is generally believed to be poor. Recent concerns over systemic adverse effects of topical corticosteroids have highlighted the risks of overdosing. Fifty patients, who were prescribed betamethasone, were prospectively studied for accuracy of compliance using a weighed dose study. Patients consistently administered inaccurate quantities of nasal corticosteroid drops, with a marked tendency to overdose up to four times the recommended daily dose (RDD) in some cases. The mean dose administered was 200 per cent of the RDD. Of the 50 patients, only seven (14 per cent) administered the correct dose. The introduction of metered-dose delivery systems should be considered to reduce the risk of inadvertent overdosing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535143     DOI: 10.1258/0022215011908694

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

Review 1.  Benefit and risk management for steroid treatment in upper airway diseases.

Authors:  Jason Krahnke; David Skoner
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

2.  Safeguarding the process of drug administration with an emphasis on electronic support tools.

Authors:  Hanna M Seidling; Anette Lampert; Kristina Lohmann; Julia T Schiele; Alexander J F Send; Diana Witticke; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 3.  Individual factors increasing complexity of drug treatment-a narrative review.

Authors:  Steffen J Schmidt; Viktoria S Wurmbach; Anette Lampert; Simone Bernard; Walter E Haefeli; Hanna M Seidling; Petra A Thürmann
Journal:  Eur J Clin Pharmacol       Date:  2020-04-01       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.